Illumina and Broad Clinical Labs usher in new era of drug discovery with collaboration to rapidly scale single-cell solutions

Longstanding partners bring together end-to-end workflows and leading CRISPR Perturb-seq technologies setting a standard for single-cell studies and enabling a 5 billion single-cell atlas ecosystem within three years SAN DIEGO, Feb. 21, 2025 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN),…